Early Syphilis Clinical Trial
Official title:
Comparisons of Treatment Response to Standard Treatment With Penicillin Between HIV-infected and HIV-uninfected Patients With Syphilis
Syphilis and HIV are prone to occur concomitantly and the two diseases share several modes
of acquisition and risk factors such as men who have sex with men (MSM), sexual workers,
intravenous drug users, previous history of sexual transmitted diseases (STDs), and multiple
partners. HIV infection rates of up to 50% have been reported among patients diagnosed with
syphilis in several regions, with higher HIV infection rates among MSM. Besides, syphilis
ulcers are proposed to enhance the transmission of HIV. In Taiwan, there is also an
increasing prevalence of syphilis and HIV co-infection among MSM. Therefore, to treat
syphilis is an important issue for public health.
According to literature review, whether patients with HIV and syphilis co-infection had
higher serologic failure rate remains controversial, especially in the era after highly
active anti-retroviral therapy (HAART) was introduced since 1996. Ghanem et al recently
demonstrated that the use of HAART may reduce syphilis failure rates among HIV-infected
patients who have syphilis. In addition, the treatment guideline in 2006 suggested that the
treatment of primary syphilis and secondary syphilis is single dose benzathine penicillin G
regardless of HIV status; however, it goes on to suggest that "some specialists recommended
additional treatments for HIV-infected patients", namely 3 doses, each a week apart. There
is no reference and evidence of strength of the suggestion but only specialists' opinion.
In the study, we aim to compare serologic response of syphilis to penicillin treatment
between HIV-infected and HIV-uninfected patients and to compare serologic response of early
syphilis (primary or secondary) to 1 dose and 3 doses of benzathine penicillin G among
HIV-infected patients. A longitudinal follow-up of serologic response will be conducted
after syphilis treatment.
n/a
Observational Model: Cohort, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03660488 -
Cefixime for Alternative Syphilis Treatment
|
Phase 2 | |
| Recruiting |
NCT05980871 -
Treatment Responses of Early Syphilis to Ceftriaxone Plus Doxycycline
|
Phase 4 |